Overview
- Two large, two-year Phase 3 studies of oral semaglutide in nearly 3,800 people with early Alzheimer’s showed no statistically significant slowing of clinical decline versus placebo.
- Novo reported improvements in certain Alzheimer’s-related biomarkers but said those changes did not translate into delayed disease progression.
- Company executive Peter Johannsen defended the program at the CTAD meeting, noting consolidated data are online, initial results will be presented Wednesday, and full results are due in March.
- Johnson & Johnson discontinued its mid-stage anti-tau antibody posdinemab after it failed to slow clinical decline, underscoring the challenge of converting biomarker shifts into patient benefit.
- A separate Phase 2b study of liraglutide in 169 patients reported roughly half the rate of brain-volume loss and an 18% cognitive advantage over one year, findings published in Nature Medicine that investigators say require larger, longer trials.